Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

American Healthcare REIT (AHR) Interest Expenses (2016 - 2025)

American Healthcare REIT (AHR) has disclosed Interest Expenses for 10 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 34.64% year-over-year to $19.8 million, compared with a TTM value of $85.8 million through Dec 2025, down 32.85%, and an annual FY2025 reading of $85.8 million, down 32.85% over the prior year.
  • Interest Expenses was $19.8 million for Q4 2025 at American Healthcare REIT, down from $20.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $42.0 million in Q3 2023 and bottomed at $4.9 million in Q2 2021.
  • Average Interest Expenses over 5 years is $28.2 million, with a median of $28.9 million recorded in 2022.
  • The sharpest move saw Interest Expenses skyrocketed 317.85% in 2022, then tumbled 37.03% in 2025.
  • Year by year, Interest Expenses stood at $36.8 million in 2021, then decreased by 5.58% to $34.8 million in 2022, then grew by 18.48% to $41.2 million in 2023, then fell by 26.43% to $30.3 million in 2024, then crashed by 34.64% to $19.8 million in 2025.
  • Business Quant data shows Interest Expenses for AHR at $19.8 million in Q4 2025, $20.4 million in Q3 2025, and $22.6 million in Q2 2025.